標(biāo)題: Titlebook: Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response; Federico Innocenti Book 2009 Humana Press 2009 DNA.Dro [打印本頁] 作者: mobility 時間: 2025-3-21 18:21
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response影響因子(影響力)
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response影響因子(影響力)學(xué)科排名
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response網(wǎng)絡(luò)公開度
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response被引頻次
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response被引頻次學(xué)科排名
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response年度引用
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response年度引用學(xué)科排名
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response讀者反饋
書目名稱Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response讀者反饋學(xué)科排名
作者: 里程碑 時間: 2025-3-21 20:31
Pharmacogenomics of the National Cancer Institute’s 60-Tumor Cell Panelmerged with drug chemosensitivity data to both elucidate a drug’s mechanism of action and to find cancer-specific targets. This framework offers a rational design strategy to mine novel anti-cancer candidates that are both potent and show specificity to targets in cancer pathways.作者: 植物群 時間: 2025-3-22 01:51
Use of Single-Nucleotide Polymorphism Array for Tumor Aberrations in Gene Copy Numbersovements in software for copy number measurement using SNP arrays. The unique ability of the SNP array to determine both the genotype and copy number has uncovered novel DNA amplification events that involve only a single allele.作者: painkillers 時間: 2025-3-22 08:12 作者: 匍匐前進 時間: 2025-3-22 09:57 作者: flutter 時間: 2025-3-22 16:11
Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patientse (TS) mRNA and protein expression significantly correlates with sensitivity and resistance to TS-targeted 5-FU based chemotherapy regimens. However, the cause of the variability in TS expression still remains unclear, even though several molecular mechanisms have been identified that seem to regula作者: flutter 時間: 2025-3-22 20:05
Impact of Polymorphisms on the Clinical Outcomes of Monoclonal Antibody Therapy Against Hematologic r impact on treatment outcomes in hematologic malignancies including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Waldenstrom’s macroglobulinemia (WM), and chronic lymphocytic leukemia (CLL). In addition, we discuss the approaches augmenting its clinical activity, especially focu作者: 譏諷 時間: 2025-3-22 23:58 作者: 好開玩笑 時間: 2025-3-23 03:25 作者: 頂點 時間: 2025-3-23 07:28 作者: Cerebrovascular 時間: 2025-3-23 12:51 作者: manifestation 時間: 2025-3-23 14:31
Book 2009tion of drug therapies in cancer patients, an aspect that received little attention, despite its importance. The availability of new molecular approaches to the selection of drug therapy is an emerging need, because the traditional approach based on the evaluation of patient and tumor characteristic作者: initiate 時間: 2025-3-23 20:54 作者: macrophage 時間: 2025-3-24 02:12
Martin Buber and Mikhail Bakhtinmerged with drug chemosensitivity data to both elucidate a drug’s mechanism of action and to find cancer-specific targets. This framework offers a rational design strategy to mine novel anti-cancer candidates that are both potent and show specificity to targets in cancer pathways.作者: Instantaneous 時間: 2025-3-24 04:22
Riikka Hofmann,Maria Vrikki,Maria Evagorouovements in software for copy number measurement using SNP arrays. The unique ability of the SNP array to determine both the genotype and copy number has uncovered novel DNA amplification events that involve only a single allele.作者: 和平 時間: 2025-3-24 06:31 作者: Conflagration 時間: 2025-3-24 13:26
Dialogues in the Philosophy of Religionerant CML. Nilotinib (Tasigna.) is undergoing FDA review. A host of other kinase inhibitors are in earlier stages of pre-clinical and clinical development. The structure–function relationships of imatinib in complex with BCR-ABL1 and the development of these new agents will certainly result in the u作者: Immunoglobulin 時間: 2025-3-24 18:36
Dialogues in the Philosophy of Religione (TS) mRNA and protein expression significantly correlates with sensitivity and resistance to TS-targeted 5-FU based chemotherapy regimens. However, the cause of the variability in TS expression still remains unclear, even though several molecular mechanisms have been identified that seem to regula作者: 詩集 時間: 2025-3-24 22:02 作者: Decrepit 時間: 2025-3-25 03:05
Dialyse und Nephrologie für Pflegeberufeenes may be good candidates for cisplatin plus either gemcitabine, etoposide, or mitomycin plus ifosfamide for optimal survival. On the same grounds, patients whose tumors have relatively high expression of these genes can still benefit from cisplatin combined with antimicrotubule drugs..The same pr作者: 遺忘 時間: 2025-3-25 05:17 作者: DEVIL 時間: 2025-3-25 07:49 作者: insert 時間: 2025-3-25 13:42 作者: arthroscopy 時間: 2025-3-25 16:59 作者: 觀察 時間: 2025-3-25 23:06
Larry A. Magliocca,Karen E. Sandersa critical role especially in the initiation, progression, and malignant potential of various cancers. In this chapter, we discuss the role of microRNAs in cancer and its potential application for cancer therapy.作者: 鐵砧 時間: 2025-3-26 01:45 作者: 高深莫測 時間: 2025-3-26 05:18 作者: 叫喊 時間: 2025-3-26 11:35 作者: Alopecia-Areata 時間: 2025-3-26 15:33
Toward the Realization of the Promise of Microarrays in Oncologyour understanding of experimental design improves, so too will the end results. We believe that with new approaches, particularly the use of pure cell populations potentially coupled with new and improved RNA amplification methodologies, the promise of microarrays for oncology finally will be realized.作者: Pepsin 時間: 2025-3-26 19:22 作者: 喃喃而言 時間: 2025-3-26 23:50
M. Milchsack,J. Silomon,F. Keller,M. Nebel with a particular focus on the methylene tetrahydrofolate and thymidylate synthase genes. While providing intriguing data that germline genetic variation may determine ALL treatment response, adequately powered prospective trials are necessary to translate these findings into clinical practice.作者: 合同 時間: 2025-3-27 03:50 作者: Inertia 時間: 2025-3-27 09:18 作者: conscience 時間: 2025-3-27 12:14
https://doi.org/10.1057/9781403978516g 2-DE and MS. Furthermore, we identified some auto-antibodies reacting to proteins in HCC cancer tissues. In this chapter, we will describe the method, our experimental result, and reports from other researchers about proteomic analysis in cancer patients.作者: projectile 時間: 2025-3-27 16:41 作者: Charlatan 時間: 2025-3-27 21:27
Rainer Nowack,Rainer Birck,Thomas Weinreichter understanding of the pharmacodynamics of 5-FU and capecitabine. Consequently, several strategies have been proposed to predict and anticipate the impact of variations in DPD on the clinical outcome of cancer patients receiving fluoropyrimidine chemotherapy.作者: Rankle 時間: 2025-3-27 23:06 作者: 射手座 時間: 2025-3-28 02:20
Thiopurines in the Treatment of Childhood Acute Lymphoblastic Leukemia and Genetic Variants of the T In this chapter, we review the role of thiopurines in the treatment of childhood ALL and provide an overview of strategies aimed at optimization of thiopurine application by therapeutic drug monitoring of thiopurine metabolites and geno- or phenotyping of TPMT.作者: prolate 時間: 2025-3-28 07:14
Dihydropyrimidine Dehydrogenase (Dpyd) Gene Polymorphism: Portrait of a Serial Killerter understanding of the pharmacodynamics of 5-FU and capecitabine. Consequently, several strategies have been proposed to predict and anticipate the impact of variations in DPD on the clinical outcome of cancer patients receiving fluoropyrimidine chemotherapy.作者: 留戀 時間: 2025-3-28 13:03
Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response978-1-60327-088-5Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: Expiration 時間: 2025-3-28 14:58
https://doi.org/10.1007/978-1-60327-088-5DNA; Drogen; MicroRNAs; Microarrays; Oncology drug development; Pharmacogenomics; Single Nucleotide Polymo作者: indecipherable 時間: 2025-3-28 20:26
Federico InnocentiComprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry.Provides a collection of multi-disciplinary topics.Covers the most impor作者: brother 時間: 2025-3-29 01:30
https://doi.org/10.1007/978-3-658-24393-7tial, however, there have been few breakthroughs that can be directly attributed to microarray-based profiling. While many researchers now say that microarrays have been over-hyped, it is more likely that early experiments were simply conducted in a na?ve manner. Many believe that as technology and 作者: 合并 時間: 2025-3-29 03:24 作者: 免費 時間: 2025-3-29 09:32 作者: Baffle 時間: 2025-3-29 14:55
Larry A. Magliocca,Karen E. Sandersslated region of target messenger RNAs. At present, hundreds of microRNAs have been identified in humans, and some of them have been revealed to play a critical role especially in the initiation, progression, and malignant potential of various cancers. In this chapter, we discuss the role of microRN作者: 食物 時間: 2025-3-29 18:25 作者: degradation 時間: 2025-3-29 22:53 作者: 討好美人 時間: 2025-3-30 00:21
Dialogues Between Physics and Mathematicsselection. However, the cancer genome is altered by many processes that could affect the expression of functional alleles in the tumor. Consequently the utility of the germline genome to predict the tumor genome is under question. Studies have suggested strong concordance between the germline and tu作者: Clinch 時間: 2025-3-30 06:17
Part I. Beyond the Doubt of a Shadowtypical member of the ErbB family of RTKs, which can form homodimers or heterodimers with other ErbB family members upon ligation with a variety of EGF-related extracellular ligands to facilitate transphosphorylation and downstream signaling..EGFR, as well as other ErbB family members and their cogn作者: 使混合 時間: 2025-3-30 09:34 作者: 使絕緣 時間: 2025-3-30 15:04 作者: 通便 時間: 2025-3-30 16:33 作者: Ingratiate 時間: 2025-3-31 00:42
https://doi.org/10.1007/978-3-540-72323-3c cancers. Rituximab, one of the commonly used monoclonal antibodies, was suggested to mediate its action mechanism via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or a direct pro-apoptotic effect. It has been proposed that the inter-individual variation作者: Priapism 時間: 2025-3-31 01:37
Dialyse und Nephrologie für Pflegeberufeg to different cisplatin-based regimens. However, this clinical observation is spurious from the molecular point of view, bewcausse DNA repair genes involved in several pathways act as differential modulators of chemosensitivity. Low expression of ERCC1 or BRCA1 predicts higher sensitivity to cispla作者: FRONT 時間: 2025-3-31 08:26
Rainer Nowack,Rainer Birck,Thomas Weinreichtive, head and neck, and breast cancers. The wide inter-patient variability observed in the pharmacokinetic profiles of these drugs is mainly caused by the erratic activity of dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for fluoropyrimidines catabolism. Beside circadian variations,作者: Inelasticity 時間: 2025-3-31 13:11 作者: acrobat 時間: 2025-3-31 17:13
Methoden zur Planung und Kontrolle,gnostic and predictive factors in breast cancer mainly focus on the clinical–pathological parameters, which are unable to reveal the diverse molecular alterations of breast cancer and are imprecise in predicting breast cancer progression and clinical outcomes. In recent years, the advances in microa作者: slipped-disk 時間: 2025-3-31 19:49 作者: engender 時間: 2025-4-1 00:38
Toward the Realization of the Promise of Microarrays in Oncologytial, however, there have been few breakthroughs that can be directly attributed to microarray-based profiling. While many researchers now say that microarrays have been over-hyped, it is more likely that early experiments were simply conducted in a na?ve manner. Many believe that as technology and
